Not yet filed. No Q3 2026 Form 13F from Paradigm Biocapital Advisors has been detected on SEC EDGAR yet. The deadline for the quarter ended Sep 30, 2026 is Monday, Nov 16, 2026.
From the fund's 2026 Q2 Form 13F (filed Aug 14, 2026) — the latest quarter fully processed on this site.
| Stock | Shares | Portfolio weight |
|---|---|---|
| RVMD · REVOLUTION MEDICINES INC | 6,361,323 | 22.31% |
| EWTX · Edgewise Therapeutics, Inc. | 10,215,455 | 7.77% |
| GMAB · GENMAB A/S | 13,133,131 | 6.76% |
| SYRE · SPYRE THERAPEUTICS INC | 3,840,778 | 6.38% |
| ORKA · Oruka Therapeutics, Inc. | 2,144,526 | 3.82% |
| TNGX · TANGO THERAPEUTICS INC | 6,357,523 | 3.72% |
| BLTE · BELITE BIO, INC | 1,232,877 | 3.55% |
| ERAS · ERASCA INC | 9,550,000 | 3.28% |
| TARS · TARSUS PHARMACEUTICALS INC | 2,775,649 | 3.27% |
| ALNY · ALNYLAM PHARMACEUTICALS, INC. | 480,000 | 2.71% |
Largest increase 2026 Q1 → 2026 Q2: ASMB (+133.6% of shares). New position in 2026 Q2: ALNY (2.71% of the portfolio). Largest trim 2026 Q1 → 2026 Q2: PCVX (-55.6% of shares). Exited in 2026 Q2: ABVX, BBOT, CYTK and 8 more.
Full record: Paradigm Biocapital Advisors fund page · manager profile & 13F-clone record · Q3 2026 season tracker.
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.